Therefore, to further improve upon its therapeutic efficacy in solid cancers we developed a novel IRE+Combo treatment protocol that combined IRE+CpG/pIC/PD-L1-Ab with the 41BB-agonist and assessed its stimulatory effects on T cell immunity and its therapeutic efficacy against lung cancer. The gene discussed is CD274; the disease is lung carcinoma.